Zealand Pharma's petrelintide, a long-acting amylin analogue, produced up to 9.2% body weight reduction over 28 weeks in 220 adults with overweight or obesity and type 2 diabetes, compared with 2.0% on placebo, alongside HbA1c reductions of up to 0.65%. Discontinuation for gastrointestinal side effects was 1.9% versus 1.7% on placebo, a tolerability profile that differs markedly from incretin-based therapies. These are topline figures from a company announcement, with full data pending presentation at a scientific conference.
Key Points
- Up to 9.2% weight loss at 28 weeks versus 2.0% placebo
- Gastrointestinal discontinuation 1.9% on drug, 1.7% on placebo
- HbA1c fell up to 0.65%; Phase 3 enrolling ~7,000 participants
Longevity Analysis
Tolerability determines whether a metabolic therapy is taken long enough to alter trajectory, and a near-placebo discontinuation rate addresses the central failure point of current weight management pharmacology. Acting through amylin rather than incretin receptors engages satiety signaling by restoring leptin sensitivity, a different entry point into the same hormonal conversation that governs appetite, glucose handling and energy partitioning. Simultaneous movement in weight and HbA1c targets the clustering of adiposity and dysglycemia that drives vascular and renal decline, though sustained benefit still depends on what accompanies the injection: nutrition, movement, and adherence maintained over years rather than months.
Original published by Longevity.Technology, by Kyle Umipig.